“Both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint. Sage plans to submit an NDA in 1H18. Brexanolone has both Breakthrough status and PRIME designation and we expect FDA approval/launch in 2H18. We have modest expectations for overall commercial opportunity w/ brexanolone as a 60-hr IV infusion, but we highlight that it will address an unmet need as the first drug approved for PPD. We ultimately expect oral ‘217 to replace brexanolone for this indication and view outcome as a positive for ‘217 program as mechanism is now validated. We still see significant upside opportunity for Sage shares w/ Phase 2 ‘217 MDD data reporting out by YE. Positive results would signify potential for broad utility across mood disorders.”,” Canaccord Genuity’s analyst wrote.
ATRA has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) reissued a neutral rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Jefferies Group LLC reissued a buy rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Zacks Investment Research raised Atara Biotherapeutics from a sell rating to a hold rating and set a $15.00 price objective on the stock in a research note on Tuesday, August 22nd. ValuEngine raised Atara Biotherapeutics from a strong sell rating to a sell rating in a research note on Friday, September 1st. Finally, BidaskClub downgraded Atara Biotherapeutics from a hold rating to a sell rating in a research note on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $24.40.
Atara Biotherapeutics (NASDAQ ATRA) opened at $13.45 on Thursday. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). equities analysts forecast that Atara Biotherapeutics will post -3.99 EPS for the current fiscal year.
WARNING: This article was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/atara-biotherapeutics-atra-buy-rating-reiterated-at-canaccord-genuity/1769283.html.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $14.75, for a total value of $112,159.00. Following the transaction, the executive vice president now directly owns 362,909 shares of the company’s stock, valued at approximately $5,352,907.75. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $13.54, for a total value of $59,576.00. Following the completion of the transaction, the chief executive officer now directly owns 737,767 shares in the company, valued at $9,989,365.18. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,209 shares of company stock worth $763,857. Company insiders own 16.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its position in Atara Biotherapeutics by 617.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares during the period. American International Group Inc. increased its position in Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the period. Schwab Charles Investment Management Inc. increased its position in Atara Biotherapeutics by 16.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock worth $1,302,000 after buying an additional 13,394 shares during the period. Vanguard Group Inc. increased its position in Atara Biotherapeutics by 10.9% in the 1st quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock worth $17,095,000 after buying an additional 81,634 shares during the period. Finally, Swiss National Bank grew its holdings in shares of Atara Biotherapeutics by 9.6% during the 1st quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after purchasing an additional 2,500 shares in the last quarter. 82.82% of the stock is currently owned by institutional investors.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with our FREE daily email newsletter.